Incyte reports Phase I/II data for epacadostat plus Keytruda ahead of ASCO

In abstracts released ahead of the American Society of Clinical Oncology meeting in Chicago next month, Incyte Corp. (NASDAQ:INCY) reported data from the Phase I/II ECHO-202 (KEYNOTE-037) trial evaluating oral epacadostat (INCB24360) plus PD-1 inhibitor Keytruda pembrolizumab from Merck & Co. Inc. (NYSE:MRK) to treat advanced cancers. Epacadostat is an indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor.

The open-label, U.S. trial’s Phase II portion evaluated twice-daily 100 mg epacadostat plus 200 mg Keytruda every 3 weeks in patients with advanced or recurrent melanoma, non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), urothelial carcinoma, triple-negative breast cancer (TNBC), squamous cell carcinoma of head and neck (SCCHN), ovarian cancer, diffuse large B cell lymphoma (DLBCL) or microsatellite instability-high (MSI-H) colorectal cancer. In Phase I portion, patients received twice-daily 25, 50, 100 or 300 mg epacadostat plus 2 mg/kg or 200 mg Keytruda every 3 weeks...